Ipca Laboratories Ltd
₹1533.90
(2.86%)
Fri, 13 Mar 2026, 01:50 am
Health Technology
Pharmaceuticals: Major
24.5KIpca Laboratories Share Price Live Chart
1 Day
0 (0%)
No Result Found
Summary
Market Cap
38872.56
Net Profit
787.53
P/B
5.48
Sector P/E
32.85
P/E
51.63
EV/EBITDA
24.19
Debt/Equity (Industry)
0.16
Interest Cover (Industry)
17.01
ROCE (Industry)
16.41
RONW (Industry)
14.52
ROE
13.61
ROCE
17.12
Debt/Equity
0.21
EPS (TTM)
41.57
Dividend Yield
0.26
Book Value
292.74
Interest Cover
15.85
Analysis
all
- Ipca Laboratories's earnings growth is expected to exceed the low risk savings rate of 7.2%.
- Ipca Laboratories's earnings are expected to exceed the low risk growth rate next year.
- Performance (ROE) is expected to be above the current IN Pharmaceuticals industry average.
- An improvement in Ipca Laboratories's performance (ROE) is expected over the next 3 years.
- Ipca Laboratories's revenue growth is expected to exceed the India market average.
- Ipca Laboratories is not paying a notable dividend for India, therefore no need to check if the payments are increasing.
- No need to calculate the sustainability of Ipca Laboratories's dividends as it is not paying a notable one for India.
- No need to calculate the sustainability of Ipca Laboratories's dividends in 3 years as they are not expected to pay a notable one for India.
- Ipca Laboratories is not paying a notable dividend for India, therefore no need to check if the payments are stable.
- Ipca Laboratories's pays a lower dividend yield than the bottom 25% of dividend payers in India (0.76%).
Shareholding
| Shareholders | DEC 2025 | SEPT 2025 | JUN 2025 | MAR 2025 | DEC 2024 |
|---|---|---|---|---|---|
| Promoters | 44.72 | 44.72 | 44.72 | 44.72 | 44.72 |
| FII | 10.63 | 10.42 | 10.67 | 10.76 | 11.07 |
| DII | 37.32 | 36.77 | 36.20 | 36.06 | 35.68 |
| Public | 7.33 | 8.08 | 8.40 | 8.46 | 8.53 |
| Government | 0 | 0 | 0 | 0 | 0 |
Technical Analysis
Support and Resistance
| Type | R3 | R2 | R1 | PP | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | 1800.57 | 1644.97 | 1586.93 | 1489.37 | 1431.33 | 1333.77 | 1178.17 |
| Fibonacci | 1644.97 | 1585.53 | 1548.81 | 1489.37 | 1429.93 | 1393.21 | 1333.77 |
| Camarilla | 1571.69 | 1557.43 | 1543.16 | 1489.37 | 1514.64 | 1500.37 | 1486.11 |
Pivots Level: Classic
R3
+311.20
1800.57
R2
+155.60
1644.97
R1
+97.57
1586.93
S1
-58.03
1431.33
S2
-155.60
1333.77
S3
-311.20
1178.17
Moving Average
Period
Value
10-EMA
1513.77
20-EMA
1499.55
30-EMA
1490.12
50-EMA
1475.21
100-EMA
1448.96
200-EMA
1427.62
Corporate Actions
| Announcement Date | Purpose | Action | Ex Date |
|---|---|---|---|
| 13 Feb 2026 | board-meetings | Quarterly Results, Nine Months Results | |
| 13 Nov 2025 | board-meetings | Quarterly Results | |
| 11 Jul 2025 | agm | ||
| 05 Jul 2025 | dividend | Final Dividend - Rs. - 2 | 05 Aug 2025 |
| 29 May 2025 | dividend | ₹2.00 Dividend /Share | 05 Aug 2025 |
| 14 Nov 2024 | dividend | ₹2.00 Dividend /Share | 27 Nov 2024 |
| 27 Oct 2024 | dividend | Interim Dividend - Rs. - 2 | 27 Nov 2024 |
| 17 Jul 2024 | agm | ||
| 06 Jul 2024 | dividend | Annual General Meeting/Dividend - Rs 2 Per Share | 07 Aug 2024 |
| 29 May 2024 | dividend | ₹2.00 Dividend /Share | 07 Aug 2024 |
Peer Comparison
Ipca Laboratories Ltd
Divis Laboratories Ltd
Dr Reddys Laboratories Ltd
Lupin Ltd
Torrent Pharmaceuticals Ltd
Sun Pharmaceutical Industries Ltd
Ipca Laboratories Ltd About
Ipca Laboratories is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulation and Active Pharmaceutical Ingredients (APIs). The Company is an integrated pharmaceutical company manufacturing and marketing.
Industry
Pharmaceuticals - Indian - Bulk Drugs & Formln
Founded
1949
Headquarters
CEO
Premchand Godha
Employees
Contact
Website
http://www.ipca.com
investors@ipca.com ; ipca@ipca.com
Phone
91-22-66474444
Location
48 Kandivli Industrial Estate, Kandivli (West), Mumbai, Maharashtra, 400067
Deals
| Client Name | Order Side | QTY | Avg Price | Date |
|---|---|---|---|---|
| USHA MADHUKAR CHANDURKAR | Sell | 4000000 | 1501.52 | 18 Dec 2024 |
| INTEGRATED CORE STRATEGIES (ASIA) PTE. LTD. | Buy | 2546497 | 2103.52 | 30 Nov 2021 |
| GOLDMAN SACHS FUNDS GOLDMAN SACHS INDIA EQUITY PORTFOLIO | Buy | 927874 | 2531.9 | 02 Sept 2021 |
| GOLDMAN SACHS INDIA FUND LIMITED | Sell | 927874 | 2531.9 | 02 Sept 2021 |
| BNP PARIBAS ARBITRAGE | Buy | 194 | 2162.44 | 27 Nov 2020 |
| INTEGRATED CORE STRATEGIES (ASIA) PTE. LTD. | Sell | 2015056 | 2158.7 | 27 Nov 2020 |
| GOLDMAN SACHS INVESTMENTS MAURITIUS I LTD | Buy | 69473 | 2173.1 | 27 Nov 2020 |
| GOLDMAN SACHS INVESTMENTS MAURITIUS I LTD | Sell | 675065 | 2173.45 | 27 Nov 2020 |
| BNP PARIBAS ARBITRAGE | Sell | 1311732 | 2154.27 | 27 Nov 2020 |
| AXIS MUTUAL FUND A/C AXIS LONG TERM EQUITY FUND | Sell | 1108795 | 453.64 | 16 Jun 2017 |
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800